Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a steady Q3 FY25 with consolidated revenue of INR 8,359 crore (+16% YoY) and EBITDA margin of 27.5%, though PAT growth was muted at 2% YoY to INR 1,413 crore. The quarter included first-time consolidation of the acquired NRT business (INR 605 crore revenue). Core business grew 7.5% YoY, with India up 40% (boosted by vaccine licensing) and Europe ex-NRT up 22%. US generics were flat YoY at $401M, impacted by price erosion and lower lenalidomide sales. Management guided for R&D spend of 8.5-9% of sales for FY25 and expects SG&A to remain around 28%. Key growth drivers include semaglutide (Canada launch Jan 2026), abatacept (filing Dec 2025), and NRT integration. Risk: US FDA Form 483 at CTO2 facility with 7 observations could delay approvals.
डॉ. रेड्डीज ने तीसरी तिमाही में 8,359 करोड़ रुपये का कारोबार किया, जो पिछले साल से 16% ज्यादा है। मुनाफा 1,413 करोड़ रुपये रहा, लेकिन इसमें सिर्फ 2% का इजाफा हुआ। कंपनी ने निकोटीन रिप्लेसमेंट थेरेपी (NRT) का नया कारोबार खरीदा है, जिससे 605 करोड़ रुपये का अतिरिक्त राजस्व मिला। भारत में कारोबार 40% बढ़ा, खासकर वैक्सीन लाइसेंसिंग से। अमेरिका में जेनेरिक दवाओं की बिक्री स्थिर रही क्योंकि कीमतें गिरीं और एक खास दवा (लेनालिडोमाइड) की बिक्री कम हुई। कंपनी अब नई दवाओं पर ध्यान दे रही है - सेमाग्लूटाइड (जनवरी 2026 में कनाडा में लॉन्च) और अबाटासेप्ट (दिसंबर 2025 में फाइलिंग)। लेकिन एक फैक्ट्री में अमेरिकी नियामक ने 7 कमियां बताई हैं, जिससे नई दवाओं की मंजूरी में देरी हो सकती है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US FDA Form 483 at CTO2 facility
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Generics Revenue
$401M
Flat YoY
Flat year-on-year; sequential decline of 10% due to lower lenalidomide and competition in Ciprodex/Suboxone.
Europe Generics Revenue (ex-NRT)
$134M
+142% YoY
Strong growth driven by NRT acquisition; ex-NRT grew 22% YoY on new launches and volume.
India Business Revenue
INR 1,346 Cr
+40% YoY
Double-digit growth aided by licensed vaccine portfolio; core growth ex-vaccine was 5%.
R&D Spend as % of Sales
8%
+25bps YoY
Investment focused on complex generics and biosimilars; guided 8.5-9% for full year.
What Changed vs Last Quarter
NEW
Semaglutide launch in Canada in January 2026
Expects to launch generic semaglutide in Canada upon patent expiry in January 2026, subject to regulatory approval.
NEW
Abatacept biosimilar filing in December 2025
Plans to file abatacept biosimilar in the US by December 2025, with potential launch in January 2027.
NEW
SG&A expenses to remain around 28% of sales
Management indicated SG&A as a percentage of sales will stay at current levels (~28%) going forward.
UPDATED
R&D spend guidance of 8.5%-9% for FY25
Management expects full-year R&D investment to be in the range of 8.5% to 9% of sales.
DROPPED
SG&A spend to be 27.5%-28% of sales for FY25
Management expects SG&A as a percentage of sales to be in the range of 27.5%-28% for the full fiscal year.
DROPPED
Normalized ETR around 25% for FY25
Management expects the normalized effective tax rate to be around 25% for the fiscal year.
DROPPED
Abatacept biosimilar launch in early calendar 2027
Management guided that the Abatacept biosimilar is expected to launch in early calendar 2027, with phase III trials nearly complete.
NEW RISK
US FDA Form 483 at CTO2 facility
The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad. Management has responded but resolution timeline is uncertain.
NEW RISK
Lenalidomide revenue decline post-2025
Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.
NEW RISK
Iron sucrose approval delay due to CRL
The company received a complete response letter (CRL) on the API side for iron sucrose, delaying the expected launch.
NEW RISK
India business underperformance in cardiac and GI segments
Cardiac and gastrointestinal therapy areas are growing slower than the market; management expects recovery but timeline is uncertain.
RISK GONE
Dependence on US FDA approvals for complex launches
Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.
RISK GONE
Revlimid revenue sustainability
Revenue from lenalidomide (Revlimid) is subject to confidential agreements and competitive pressures; management declined to provide specific guidance on future sales.
RISK GONE
Currency risk in Russia
Russia business faces unfavorable forex movements; despite hedging, devaluation could impact reported revenues.
RISK GONE
Impairment risk from supply chain issues
A product faced procurement constraints from contract manufacturers, leading to a ₹92 crore impairment; similar issues could affect other products.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q3 FY24, Q4 FY24
Pricing pressure in some key products partially offset volume gains in North America.
Mentioned in Q2 FY24, Q3 FY24, Q4 FY24
Excluding divestment income, India business is expected to continue double-digit growth, driven by new product launches and partnerships.
Mentioned in Q2 FY24, Q2 FY25
Management guided that the Abatacept biosimilar is expected to launch in early calendar 2027, with phase III trials nearly complete.
Fast read
Guidance and risk preview
Management expects full-year R&D investment to be in the range of 8.5% to 9% of sales.
The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad.
View Risks →